US20210353539A1 - Aqueous Preparation for External Use - Google Patents

Aqueous Preparation for External Use Download PDF

Info

Publication number
US20210353539A1
US20210353539A1 US17/382,272 US202117382272A US2021353539A1 US 20210353539 A1 US20210353539 A1 US 20210353539A1 US 202117382272 A US202117382272 A US 202117382272A US 2021353539 A1 US2021353539 A1 US 2021353539A1
Authority
US
United States
Prior art keywords
acid
external use
aqueous preparation
preparation
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/382,272
Inventor
Katsuhiro Yamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedRx Co Ltd
Original Assignee
MedRx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedRx Co Ltd filed Critical MedRx Co Ltd
Priority to US17/382,272 priority Critical patent/US20210353539A1/en
Publication of US20210353539A1 publication Critical patent/US20210353539A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to an aqueous preparation for external use comprising an acidic drug or a salt thereof as an active ingredient.
  • anti-inflammatory analgetic preparations for external use such as phenylacetic acid nonsteroidal anti-inflammatory analgetics like Diclofenac, and propionic acid nonsteroidal anti-inflammatory analgetics like Loxoprofen are broadly known, and various techniques for improving percutaneous absorbability of drugs have been proposed (e.g. Patent Documents 1 to 6).
  • An object of the present invention is to provide an aqueous preparation for external use having an excellent percutaneous absorbability of acidic drugs and giving a good feeling in use.
  • the present inventors found that the aforementioned problem could be solved by an aqueous preparation for external use comprising isostearic acid and alkanolamine, and completed the present invention. That is, the present invention provides an aqueous preparation for external use comprising an acidic drug or a salt thereof, isostearic acid and alkanolamine.
  • the aqueous preparation for external use according to the present invention further comprises a C 2-6 aliphatic hydroxy acid, and has pH 4.5 to 7.8.
  • the C 2-6 aliphatic hydroxy acid may be one acid or a combination of two or more acids selected from a group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
  • the acidic drug is preferably an arylacetic acid nonsteroidal anti-inflammatory analgetic.
  • the aqueous preparation for external use according to the present invention further comprises glycerin.
  • the aqueous preparation for external use according to the present invention has an excellent percutaneous absorbability, and particularly when the drug is an anti-inflammatory analgetic such as an arylacetic acid nonsteroidal anti-inflammatory analgetic, the preparation is expected to exhibit a sufficient anti-inflammatory analgetic effect in a short time.
  • an anti-inflammatory analgetic such as an arylacetic acid nonsteroidal anti-inflammatory analgetic
  • the aqueous preparation for external use according to the present invention can also be suitably used as a liquid preparation which gives a good feeling in use and is used by being put into an applicator with a foamed resin or ball attached to its tip.
  • FIG. 1 is a graph showing a result of a rat skin permeability test for the aqueous preparations for external use according to the present invention prepared in Examples 3, 5 and 11, and a commercially available 1% Diclofenac sodium liquid preparation.
  • FIG. 2 is a graph showing a result of a human skin permeability test for the aqueous preparation for external use according to the present invention prepared in Example 12 and a commercially available 1% Diclofenac sodium gel preparation.
  • the aqueous preparation for external use according to the present invention comprises an acidic drug or a salt thereof as an active ingredient.
  • the acidic drug can be exemplified by a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Alclofenac, Diclofenac and Felbinac; an indoleacetic acid nonsteroidal anti-inflammatory analgetic such as Indomethacin, Etodolac and Acemetacin; a salicylic acid nonsteroidal anti-inflammatory analgetic such as salicylic acid, Aspirin, Ethenzamide and Diflunisal; a propionic acid nonsteroidal anti-inflammatory analgetic such as Ibuprofen, Ketoprofen, Zaltoprofen, Suprofen, Pranoprofen, Flurbiprofen and Loxoprofen; a fenamic acid nonsteroidal anti-inflammatory analgetic such as mefenamic acid; an antibiotic such as Cefa
  • the arylacetic acid nonsteroidal anti-inflammatory analgetics such as the phenylacetic acid nonsteroidal anti-inflammatory analgetic and the indoleacetic acid nonsteroidal anti-inflammatory analgetic are preferable, and the phenylacetic acid nonsteroidal anti-inflammatory analgetic is particularly preferred.
  • the salt of the acidic drug which may be used in the present invention can be exemplified by an alkali metal salt such as sodium and potassium; an alkaline earth metal salt such as calcium and magnesium; an ammonium salt; an alkylamine salt such as dimethylamine, diethylamine and trimethylamine; and a cyclic amine salt such as epolamine (hydroxyethylpyrrolidine salt); and the like.
  • the content of the acidic drug or the salt thereof is not particularly limited but can be selected from a range of e.g. 0.1 to 20 wt %, preferably 0.1 to 10 wt %, particularly preferably 0.5 to 5 wt %. In a case that the content of the acidic drug or the salt thereof is less than the above range, a sufficient drug efficacy may not be obtained, and thus the case is not preferable. In a case that the content of the acidic drug or the salt thereof is more than the above range, the acidic drug or the salt thereof may not be sufficiently dissolved, or otherwise crystals may precipitate over time, and thus the case is not preferable.
  • the aqueous preparation for external use according to the present invention comprises water as an essential constituent and is typically represented by a liquid preparation, but can be applied to a gel, a cream, a cataplasm and the like.
  • a solution prepared by dissolving an acidic drug or a salt thereof, an isostearic acid, and an alkanolamine, and a C 2-6 aliphatic hydroxy acid if necessary in a mixture of water and a lower alcohol is a preferable mode of the present invention.
  • the content of the isostearic acid may be selected from a range of e.g. 0.5 to 20 wt %, preferably 2 to 15 wt %, particularly preferably 3 to 10 wt % of the weight of the aqueous preparation for external use.
  • it can be selected from a range of 0.1 to 8 times by mol, preferably 0.5 to 3 times by mol, more preferably 1.0 to 2.5 times by mol, particularly preferably 1.5 to 2.4 times by mol with respect to the acidic drug or the salt thereof.
  • alkanolamine any of e.g. primary, secondary or tertiary alkanolamines having about 2 to 12 carbon atoms can be used, but tertiary alkanolamines such as triethanolamine and triisopropanolamine are preferred.
  • the content of the alkanolamine can be selected from a range of 0.4 to 8.0 times by mol, preferably 0.5 to 4.0 times by mol with respect to the content of the isostearic acid.
  • the acidic drug is a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Diclofenac
  • the content of the alkanolamine may be selected from a range of 0.4 to 1.5 times by mol, particularly preferably 0.6 to 1.2 times by mol with respect to the content of the isostearic acid.
  • the content of the alkanolamine may be selected from a range of 2.5 to 8.0 times by mol, preferably 3.0 to 4.0 times by mol with respect to the content of the isostearic acid.
  • the content of the alkanolamine can be selected from a range of e.g. 0.2 to 2.5 times by mol, preferably 0.3 to 1.2 times by mol, particularly preferably 0.4 to 0.8 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid.
  • the aqueous preparation for external use may not be a uniform solution, or otherwise may be separated over time or by stimulation of shake or the like, and thus the case is not preferable.
  • the acidic drug is a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Diclofenac
  • the content of the alkanolamine is 0.6 to 1.2 times by mol with respect to the content of the isostearic acid, and 0.3 to 0.5 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid.
  • the acidic drug is an indoleacetic acid nonsteroidal anti-inflammatory analgetic such as Indomethacin
  • the content of the alkanolamine is 3.0 to 4.5 times by mol with respect to the content of the isostearic acid, and 0.6 to 0.9 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid.
  • the C 2-6 aliphatic hydroxy acid can be exemplified by lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
  • One of or a combination of two or more C 2-6 aliphatic hydroxy acids can be used.
  • the solubility of the acidic drug can be enhanced to obtain a stable external preparation which does not cause crystal precipitation, separation and the like even after long preservation, and furthermore the percutaneous absorbability of the acidic drug is improved.
  • the aqueous preparation for external use comprising the isostearic acid and the alkanolamine
  • the acidity or alkalinity becomes acidic
  • it become easy to separate but it becomes a stable liquid preparation by containing the C 2-6 aliphatic hydroxy acid.
  • the content of the C 2-6 aliphatic hydroxy acid can be appropriately adjusted so that the liquidity of the aqueous preparation for external use is within an appropriate range described below without any particular limitation.
  • it may be selected from a range of 1.0 to 10 times by mol, preferably 1.0 to 5.0 times by mol, particularly preferably 1.5 to 3.5 times by mol with respect to the acidic drug.
  • the C 2-6 aliphatic hydroxy acid preferably comprises at least a tartaric acid or a lactic acid, and particularly preferably comprises a tartaric acid.
  • the inclusion of the tartaric acid improves not only the stability but also particularly the percutaneous of the aqueous preparation for external use. This may be because the tartaric acid is readily soluble in both an aqueous solvent and a fatty solvent, so that after applying the aqueous preparation for external use to the skin, it can remain in a dissolved state even after aqueous solvents such as water and alcohol evaporate, and thus it is easy to penetrate into the skin.
  • the acidity or alkalinity of the aqueous preparation for external use according to the present invention may be selected from a range of pH 4.5 to 7.8, preferably pH 5.6 to 7.5, more preferably pH 5.0 to 6.8, particularly preferably pH 5.0 to 5.8, most preferably pH 5.2 to 5.5.
  • pH is out of the above range
  • the stability of the aqueous preparation for external use may deteriorate e.g. crystals are precipitated over time, and skin stimulation or the like may be caused, and thus the case is not preferable.
  • the pH of the aqueous preparation for external use can be adjusted according to the contents of the isostearic acid, the alkanolamine and the hydroxy acid described above, it may be further adjusted by using a pH adjuster such as hydrochloric acid, sodium hydroxide and potassium hydroxide.
  • a pH adjuster such as hydrochloric acid, sodium hydroxide and potassium hydroxide.
  • a lower alcohol used as a solvent by mixing with water can be exemplified by monovalent or divalent alcohols having 2 to 5 carbon atoms such as ethanol, propanol, isopropanol and propylene glycol.
  • monovalent or divalent alcohols having 2 to 5 carbon atoms such as ethanol, propanol, isopropanol and propylene glycol.
  • the content of the lower alcohol may be selected from a range of e.g. 20 to 70 wt %, preferably 40 to 60 wt % in view of e.g. the solubility, the feeling in use and the like of the diclofenac or the salt thereof.
  • the isopropanol and the propylene glycol are used in combination in a ratio of e.g. 1:3 to 3:1, preferably 1:2 to 2:1, particularly preferably 1:1 to 1:2.
  • the aqueous preparation for external use according to the present invention comprises at least 10 wt %, preferably 20 wt %, particularly preferably not less than 25 wt % of water.
  • the external preparation according to the present invention further comprises glycerin.
  • glycerin can provide an external preparation having excellent immediate effectiveness in which a skin permeation rate of the acidic drug or the salt thereof is improved and after applied to a skin, the acidic drug or the salt thereof rapidly permeates into the skin.
  • the content of glycerin can be selected from a range of e.g. 0.1 to 10 wt %, preferably 0.2 to 5 wt %, particularly preferably 0.2 to 1.0 wt %.
  • the effect of improving the permeation rate is hardly obtained, and also in a case that the content is more than the above ranges, the effect is not enhanced, and far from that, the skin permeability may be inferior, and thus the cases are not preferable.
  • the aqueous preparation for external use according to the present invention may further comprise a lipophilic component as a solubilizer or a percutaneous absorption promoter for the acidic drug or the salt thereof.
  • the lipophilic component can be blended in a range of less than 20 wt %, preferably less than 15 wt % of the aqueous preparation for external use.
  • the lipophilic component can be exemplified by fatty acid esters such as isopropyl myristate, isopropyl palmitate and diethyl sebacate; an N-methylpyrrolidone; a dimethyl isosorbide; and the like. Among them, the N-methylpyrrolidone or the dimethyl isosorbide is preferable.
  • the aqueous preparation for external use according to the present invention may comprise additives such as a thickening agent, a moisturizer, a dissolution aid, a stabilizer and a perfume, as necessary.
  • the thickening agent can be exemplified by celluloses such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, carmellose, carmellose sodium and carmellose calcium; polyvinylpyrrolidone; polyvinyl alcohol; carboxyvinyl polymer; a polyacrylate such as sodium polyacrylate; and the like.
  • the content of the thickening agent can be selected from a range of e.g. 0.05 to 20 wt %.
  • the aqueous preparation for external use according to the present invention is a liquid preparation, it can be selected from a range of 0.05 to 0.5 wt %.
  • the stabilizer can be exemplified by sodium sulfite, sodium pyrosulfite and the like.
  • Aqueous preparations for external use having the compositions (wt %) shown in Table 1 and Table 2 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are collectively shown in Tables 1 and 2.
  • the appearance was evaluated according to the following criteria.
  • ⁇ Clear solution ⁇ : A transparent solution was obtained, but it separated into an oil phase and an aqueous phase over time or by stimulation of shake or the like
  • a skin permeability test using a franz cell was carried out according to a conventional method for the produced aqueous preparation for external use and a commercially available 1% Diclofenac sodium liquid preparation.
  • skins excised from abdomens of rats (5 weeks old, Wistar rat, male) were used. Sampling was carried out 2, 4, and 6 hours after the start of the test. The cumulative permeation amounts after 6 hours are shown in Tables 1 and 2 altogether.
  • a graph indicating transitions of the cumulative skin permeation amounts of the preparations of Examples 3, 5 and 11 and the commercially available liquid preparation is shown in FIG. 1 .
  • the aqueous preparations for external use of Examples 1 and 2 of the present invention comprising the isostearic acid and the alkanolamine showed a higher skin permeability compared to the preparation of Comparative Example 5 which does not comprise both of them.
  • the liquid preparations of Comparative Examples 1 to 4 comprising a decanoic acid and a levulinic acid as fatty acids instead of the isostearic acid had skin permeability inferior to that of the preparation of Comparative Example 5.
  • the preparation of Example 3 showed skin permeability superior to that of the preparation of Example 2 by further containing a lactic acid.
  • the preparation of Example 4 showed skin permeability superior to that of the preparation of Example 3 by further containing glycerin.
  • aqueous preparations for external use of Examples 4 to 11 comprising 4 to 6 wt % of isostearic acid showed good skin permeability. There was a tendency that, among them, the preparations having higher contents of the isostearic acid showed superior skin permeability. There was a tendency that the aqueous preparations for external use of Examples 7 to 9 having low contents of the organic amine showed somewhat inferior skin permeability.
  • the aqueous preparation for external use according to the present invention had excellent skin permeability and showed up to about 3 times the Diclofenac skin permeability of the commercially available Diclofenac sodium liquid preparation.
  • the liquid preparation of Example 5 comprising glycerin had a high permeation rate.
  • Aqueous preparations for external use having the compositions (wt %) shown in Table 3 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are shown in Table 3 altogether.
  • the appearance was evaluated according to the following criteria.
  • ⁇ Clear solution ⁇ : A transparent solution was obtained, but it separated into an oil phase and an aqueous phase over time or by stimulation of shake or the like
  • a skin permeability test using the franz cell was carried out according to the conventional method for the aqueous preparations for external use of Examples 12 to 15.
  • skins of swines (Yucatan Micropig, male, 5 months old) were used. Sampling was carried out 8 and 24 hours after the start of the test.
  • the cumulative skin permeation amounts ( ⁇ g/cm 2 ) are shown altogether in Table 3.
  • a human skin permeability test using the franz cell was carried out according to the conventional method for the prepared aqueous preparation for external use of Example 12 and a commercially available 1% diclofenac sodium gel preparation.
  • a graph indicating transitions of the cumulative skin permeation amounts of the diclofenac is shown in FIG. 2 .
  • Aqueous preparations for external use comprising indomethacin as an active ingredient having the compositions (wt %) shown in Table 4 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are shown in Table 4.
  • the appearance was evaluated according to the following criterion.
  • a skin permeability test using the franz cell was carried out according to the conventional method for the aqueous preparations for external use of Examples 2-1 to 2-5 and the commercially available 1% Indomethacin liquid preparation.
  • skins of swines (Yucatan Micropig, male, 5 months old) were used.
  • the cumulative skin permeation amounts ( ⁇ g/cm 2 ) until 24 hours after the start of the test are shown in Table 4.
  • the aqueous preparation for external use according to the present invention can be utilized as a liquid preparation which rapidly express an excellent anti-inflammatory analgetic effect, particularly as a liquid preparation which is used by being put into an applicator with a foamed resin or ball attached to its tip.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The purpose of the present invention is to provide an aqueous preparation for external use, said aqueous preparation comprising an acidic drug such as an arylacetic acid nonsteroidal anti-inflammatory analgesic, having an excellent percutaneous absorbability and giving a good feeling in use. The aqueous preparation for external use comprises the acidic drug or a salt thereof, isostearic acid and an alkanol amine. It is preferred that the aqueous preparation according to the present invention for external use further comprises a C2-6 aliphatic hydroxy acid and has a pH value of 4.5-7.8. The C2-6 aliphatic hydroxy acid is one member or a combination of the same selected from the group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.

Description

    TECHNICAL FIELD
  • The present invention relates to an aqueous preparation for external use comprising an acidic drug or a salt thereof as an active ingredient.
    • BACKGROUND ART
  • As the external preparation of the acidic drug, anti-inflammatory analgetic preparations for external use such as phenylacetic acid nonsteroidal anti-inflammatory analgetics like Diclofenac, and propionic acid nonsteroidal anti-inflammatory analgetics like Loxoprofen are broadly known, and various techniques for improving percutaneous absorbability of drugs have been proposed (e.g. Patent Documents 1 to 6).
    • PRIOR ART DOCUMENTS Patent Documents
    • Patent document 1: JP H07-173058 A
    • Patent document 2: JP H10-182450 A
    • Patent document 3: JP 2005-336063 A
    • Patent document 4: JP 2014-208623 A
    • Patent document 5: JP 2014-172857 A
    • Patent document 6: JP 2014-101338 A
    SUMMARY OF THE INVENTION Problems to be Solved by the Invention
  • An object of the present invention is to provide an aqueous preparation for external use having an excellent percutaneous absorbability of acidic drugs and giving a good feeling in use.
    • Means for Solving Problems
  • As a result of intensive studies, the present inventors found that the aforementioned problem could be solved by an aqueous preparation for external use comprising isostearic acid and alkanolamine, and completed the present invention. That is, the present invention provides an aqueous preparation for external use comprising an acidic drug or a salt thereof, isostearic acid and alkanolamine.
  • Preferably, the aqueous preparation for external use according to the present invention further comprises a C2-6 aliphatic hydroxy acid, and has pH 4.5 to 7.8.
  • The C2-6 aliphatic hydroxy acid may be one acid or a combination of two or more acids selected from a group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
  • The acidic drug is preferably an arylacetic acid nonsteroidal anti-inflammatory analgetic.
  • Preferably, the aqueous preparation for external use according to the present invention further comprises glycerin.
    • Effects of the Invention
  • The aqueous preparation for external use according to the present invention has an excellent percutaneous absorbability, and particularly when the drug is an anti-inflammatory analgetic such as an arylacetic acid nonsteroidal anti-inflammatory analgetic, the preparation is expected to exhibit a sufficient anti-inflammatory analgetic effect in a short time.
  • The aqueous preparation for external use according to the present invention can also be suitably used as a liquid preparation which gives a good feeling in use and is used by being put into an applicator with a foamed resin or ball attached to its tip.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is a graph showing a result of a rat skin permeability test for the aqueous preparations for external use according to the present invention prepared in Examples 3, 5 and 11, and a commercially available 1% Diclofenac sodium liquid preparation.
  • FIG. 2 is a graph showing a result of a human skin permeability test for the aqueous preparation for external use according to the present invention prepared in Example 12 and a commercially available 1% Diclofenac sodium gel preparation.
    •  MODE FOR CARRYING OUT THE INVENTION
  • The aqueous preparation for external use according to the present invention comprises an acidic drug or a salt thereof as an active ingredient. The acidic drug can be exemplified by a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Alclofenac, Diclofenac and Felbinac; an indoleacetic acid nonsteroidal anti-inflammatory analgetic such as Indomethacin, Etodolac and Acemetacin; a salicylic acid nonsteroidal anti-inflammatory analgetic such as salicylic acid, Aspirin, Ethenzamide and Diflunisal; a propionic acid nonsteroidal anti-inflammatory analgetic such as Ibuprofen, Ketoprofen, Zaltoprofen, Suprofen, Pranoprofen, Flurbiprofen and Loxoprofen; a fenamic acid nonsteroidal anti-inflammatory analgetic such as mefenamic acid; an antibiotic such as Cefazolin, Penicillamine, Imipenem and Cilastatin; a barbituric acid drug such as Thiopental, Pentobarbital, Amobarbital and Phenobarbital; an antiallergenic such as cromoglycic acid; and an HMG-CoA reductase inhibitor such as Pravastatin, Rosuvastatin, Atorvastatin and Simvastatin. Among them, the arylacetic acid nonsteroidal anti-inflammatory analgetics such as the phenylacetic acid nonsteroidal anti-inflammatory analgetic and the indoleacetic acid nonsteroidal anti-inflammatory analgetic are preferable, and the phenylacetic acid nonsteroidal anti-inflammatory analgetic is particularly preferred. The salt of the acidic drug which may be used in the present invention can be exemplified by an alkali metal salt such as sodium and potassium; an alkaline earth metal salt such as calcium and magnesium; an ammonium salt; an alkylamine salt such as dimethylamine, diethylamine and trimethylamine; and a cyclic amine salt such as epolamine (hydroxyethylpyrrolidine salt); and the like.
  • The content of the acidic drug or the salt thereof is not particularly limited but can be selected from a range of e.g. 0.1 to 20 wt %, preferably 0.1 to 10 wt %, particularly preferably 0.5 to 5 wt %. In a case that the content of the acidic drug or the salt thereof is less than the above range, a sufficient drug efficacy may not be obtained, and thus the case is not preferable. In a case that the content of the acidic drug or the salt thereof is more than the above range, the acidic drug or the salt thereof may not be sufficiently dissolved, or otherwise crystals may precipitate over time, and thus the case is not preferable.
  • The aqueous preparation for external use according to the present invention comprises water as an essential constituent and is typically represented by a liquid preparation, but can be applied to a gel, a cream, a cataplasm and the like. For example, a solution prepared by dissolving an acidic drug or a salt thereof, an isostearic acid, and an alkanolamine, and a C2-6 aliphatic hydroxy acid if necessary in a mixture of water and a lower alcohol is a preferable mode of the present invention.
  • Although it is known to use a fatty acid as a percutaneous absorption promoter, use of the isostearic acid exponentially improves the percutaneous absorbability of the drug compared to use of other fatty acids, in the aqueous preparation for external use comprising the acidic drug. In particular, when the acidic drug is an arylacetic acid nonsteroidal anti-inflammatory analgetic, the percutaneous absorption promoting effect by addition of the isostearic acid is remarkable. The content of the isostearic acid may be selected from a range of e.g. 0.5 to 20 wt %, preferably 2 to 15 wt %, particularly preferably 3 to 10 wt % of the weight of the aqueous preparation for external use. Furthermore, it can be selected from a range of 0.1 to 8 times by mol, preferably 0.5 to 3 times by mol, more preferably 1.0 to 2.5 times by mol, particularly preferably 1.5 to 2.4 times by mol with respect to the acidic drug or the salt thereof.
  • As the alkanolamine, any of e.g. primary, secondary or tertiary alkanolamines having about 2 to 12 carbon atoms can be used, but tertiary alkanolamines such as triethanolamine and triisopropanolamine are preferred.
  • The content of the alkanolamine can be selected from a range of 0.4 to 8.0 times by mol, preferably 0.5 to 4.0 times by mol with respect to the content of the isostearic acid. When the acidic drug is a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Diclofenac, the content of the alkanolamine may be selected from a range of 0.4 to 1.5 times by mol, particularly preferably 0.6 to 1.2 times by mol with respect to the content of the isostearic acid. When the acidic drug is an indoleacetic acid nonsteroidal anti-inflammatory analgetic such as Indomethacin, the content of the alkanolamine may be selected from a range of 2.5 to 8.0 times by mol, preferably 3.0 to 4.0 times by mol with respect to the content of the isostearic acid.
  • When the aqueous preparation for external use further comprises the C2-6 aliphatic hydroxy acid described below, the content of the alkanolamine can be selected from a range of e.g. 0.2 to 2.5 times by mol, preferably 0.3 to 1.2 times by mol, particularly preferably 0.4 to 0.8 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid. In a case that the amount of the added alkanolamine is out of the above ranges, the aqueous preparation for external use may not be a uniform solution, or otherwise may be separated over time or by stimulation of shake or the like, and thus the case is not preferable.
  • When the acidic drug is a phenylacetic acid nonsteroidal anti-inflammatory analgetic such as Diclofenac, it is preferred that the content of the alkanolamine is 0.6 to 1.2 times by mol with respect to the content of the isostearic acid, and 0.3 to 0.5 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid. When the acidic drug is an indoleacetic acid nonsteroidal anti-inflammatory analgetic such as Indomethacin, it is preferred that the content of the alkanolamine is 3.0 to 4.5 times by mol with respect to the content of the isostearic acid, and 0.6 to 0.9 times by mol with respect to the sum of the isostearic acid and the aliphatic hydroxy acid.
  • The C2-6 aliphatic hydroxy acid can be exemplified by lactic acid, glycolic acid, malic acid, tartaric acid and citric acid. One of or a combination of two or more C2-6 aliphatic hydroxy acids can be used. When the property of the aqueous preparation for external use is adjusted to an appropriate range by containing the C2-6 aliphatic hydroxy acid, the solubility of the acidic drug can be enhanced to obtain a stable external preparation which does not cause crystal precipitation, separation and the like even after long preservation, and furthermore the percutaneous absorbability of the acidic drug is improved. In relation to the aqueous preparation for external use according to the present invention comprising the isostearic acid and the alkanolamine, when its acidity or alkalinity becomes acidic, it become easy to separate, but it becomes a stable liquid preparation by containing the C2-6 aliphatic hydroxy acid. The content of the C2-6 aliphatic hydroxy acid can be appropriately adjusted so that the liquidity of the aqueous preparation for external use is within an appropriate range described below without any particular limitation. For example, it may be selected from a range of 1.0 to 10 times by mol, preferably 1.0 to 5.0 times by mol, particularly preferably 1.5 to 3.5 times by mol with respect to the acidic drug.
  • The C2-6 aliphatic hydroxy acid preferably comprises at least a tartaric acid or a lactic acid, and particularly preferably comprises a tartaric acid. The inclusion of the tartaric acid improves not only the stability but also particularly the percutaneous of the aqueous preparation for external use. This may be because the tartaric acid is readily soluble in both an aqueous solvent and a fatty solvent, so that after applying the aqueous preparation for external use to the skin, it can remain in a dissolved state even after aqueous solvents such as water and alcohol evaporate, and thus it is easy to penetrate into the skin. A combination of the tartaric acid and the lactic acid is preferably used as the C2-6 aliphatic hydroxy acid. When the tartaric acid and the lactic acid are used in combination, their compounding ratio may be selected from a range of tartaric acid:lactic acid=1:1 to 1:3.
  • The acidity or alkalinity of the aqueous preparation for external use according to the present invention may be selected from a range of pH 4.5 to 7.8, preferably pH 5.6 to 7.5, more preferably pH 5.0 to 6.8, particularly preferably pH 5.0 to 5.8, most preferably pH 5.2 to 5.5. In a case that pH is out of the above range, the stability of the aqueous preparation for external use may deteriorate e.g. crystals are precipitated over time, and skin stimulation or the like may be caused, and thus the case is not preferable. Although the pH of the aqueous preparation for external use can be adjusted according to the contents of the isostearic acid, the alkanolamine and the hydroxy acid described above, it may be further adjusted by using a pH adjuster such as hydrochloric acid, sodium hydroxide and potassium hydroxide.
  • A lower alcohol used as a solvent by mixing with water can be exemplified by monovalent or divalent alcohols having 2 to 5 carbon atoms such as ethanol, propanol, isopropanol and propylene glycol. One of or a combination of two or more lower alcohols can be used. The content of the lower alcohol may be selected from a range of e.g. 20 to 70 wt %, preferably 40 to 60 wt % in view of e.g. the solubility, the feeling in use and the like of the diclofenac or the salt thereof. In the present invention, it is preferred that the isopropanol and the propylene glycol are used in combination in a ratio of e.g. 1:3 to 3:1, preferably 1:2 to 2:1, particularly preferably 1:1 to 1:2.
  • The aqueous preparation for external use according to the present invention comprises at least 10 wt %, preferably 20 wt %, particularly preferably not less than 25 wt % of water.
  • Preferably, the external preparation according to the present invention further comprises glycerin. The inclusion of glycerin can provide an external preparation having excellent immediate effectiveness in which a skin permeation rate of the acidic drug or the salt thereof is improved and after applied to a skin, the acidic drug or the salt thereof rapidly permeates into the skin. The content of glycerin can be selected from a range of e.g. 0.1 to 10 wt %, preferably 0.2 to 5 wt %, particularly preferably 0.2 to 1.0 wt %. In a case that the content of glycerin is less than the above ranges, the effect of improving the permeation rate is hardly obtained, and also in a case that the content is more than the above ranges, the effect is not enhanced, and far from that, the skin permeability may be inferior, and thus the cases are not preferable.
  • The aqueous preparation for external use according to the present invention may further comprise a lipophilic component as a solubilizer or a percutaneous absorption promoter for the acidic drug or the salt thereof. The lipophilic component can be blended in a range of less than 20 wt %, preferably less than 15 wt % of the aqueous preparation for external use. The lipophilic component can be exemplified by fatty acid esters such as isopropyl myristate, isopropyl palmitate and diethyl sebacate; an N-methylpyrrolidone; a dimethyl isosorbide; and the like. Among them, the N-methylpyrrolidone or the dimethyl isosorbide is preferable.
  • The aqueous preparation for external use according to the present invention may comprise additives such as a thickening agent, a moisturizer, a dissolution aid, a stabilizer and a perfume, as necessary. The thickening agent can be exemplified by celluloses such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, carmellose, carmellose sodium and carmellose calcium; polyvinylpyrrolidone; polyvinyl alcohol; carboxyvinyl polymer; a polyacrylate such as sodium polyacrylate; and the like. The content of the thickening agent can be selected from a range of e.g. 0.05 to 20 wt %. When the aqueous preparation for external use according to the present invention is a liquid preparation, it can be selected from a range of 0.05 to 0.5 wt %. The stabilizer can be exemplified by sodium sulfite, sodium pyrosulfite and the like.
    • EXAMPLES
  • Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited by these Examples at all.
    • [Production of the Aqueous Preparation for External Use]
  • Aqueous preparations for external use having the compositions (wt %) shown in Table 1 and Table 2 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are collectively shown in Tables 1 and 2.
  • The appearance was evaluated according to the following criteria.
  • ∘: Clear solution
    Δ: A transparent solution was obtained, but it separated into an oil phase and an aqueous phase over time or by stimulation of shake or the like
    • [Skin Permeability Test]
  • A skin permeability test using a franz cell was carried out according to a conventional method for the produced aqueous preparation for external use and a commercially available 1% Diclofenac sodium liquid preparation. For the test, skins excised from abdomens of rats (5 weeks old, Wistar rat, male) were used. Sampling was carried out 2, 4, and 6 hours after the start of the test. The cumulative permeation amounts after 6 hours are shown in Tables 1 and 2 altogether. A graph indicating transitions of the cumulative skin permeation amounts of the preparations of Examples 3, 5 and 11 and the commercially available liquid preparation is shown in FIG. 1.
  • TABLE 1
    Comp Comp Comp Comp Comp
    Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5
    D28 D20 D63 D67 D31 D32 D35 D36 D25
    Diclofenac Na
    10 10 10 10 10 10 10 10 10
    Isostearic acid 40 40 40 40
    Decanoic acid 40 40
    Levulinic acid 40 40
    Lactic acid 10 10
    Triisopropanolamine 40 40 40
    Triethanolamine 40 40 40 40 40
    Glycerin 10
    Isopropanol 200 200 200 200 200 200 200 200 200
    Pure water 305 305 300 295 305 305 305 305 345
    Propylene glycol 305 305 300 295 305 305 305 305 345
    Dimethyl isosorbide 100 100 100 100 100 100 100 100 100
    total 1000 1000 1000 1000 1000 1000 1000 1000 1000
    pH 7.5 7.8 5.5 7.8 6.7 7.1 5.8 6.0 6.2
    Appearance ○ ○
    Figure US20210353539A1-20211118-P00001
    		 ○ ○ ○ ○ ○ ○
    Cumulative skin 85.6 99.6 108 145.0 9.1 5.3 10.0 4.7 19.2
    permeation amount (6 hr)
  • The aqueous preparations for external use of Examples 1 and 2 of the present invention comprising the isostearic acid and the alkanolamine showed a higher skin permeability compared to the preparation of Comparative Example 5 which does not comprise both of them. The liquid preparations of Comparative Examples 1 to 4 comprising a decanoic acid and a levulinic acid as fatty acids instead of the isostearic acid had skin permeability inferior to that of the preparation of Comparative Example 5. The preparation of Example 3 showed skin permeability superior to that of the preparation of Example 2 by further containing a lactic acid. The preparation of Example 4 showed skin permeability superior to that of the preparation of Example 3 by further containing glycerin.
  • TABLE 2
    Ex. 5 Ex. 6 Ex. 7 Ex. 8 Ex. 9 Ex. 4 Ex. 10 Ex. 11
    D70 D72 D76 D80 D78 D67 D73 D66
    Diclofenac Na
    10 10 10 10 10 10 10 10
    Isostearic acid 55 50 55 55 55 40 55 60
    Lactic acid 10 10 10 10 7 10 10 10
    Triethanolamine 40 40 35 30 33 40 40 40
    Glycerin 5 5 5 5 5 10 10
    Isopropanol 200 200 200 200 200 200 195 200
    Pure water 295 295 295 295 295 295 295 295
    Propylene glycol 295 295 295 305 295 295 295 295
    Dimethyl isosorbide 90 95 92 90 100 100 90 90
    total 1000 1000 1000 1000 1000 1000 1000 1000
    pH 7.3 7.3 7.3 — — 7.5 7.3 7.3
    Appearance ○ ○ ○
    Figure US20210353539A1-20211118-P00002
    		 ○ ○ ○ ○
    Cumulative skin 175.2 165.3 115.6 103.1 94.6 145.1 162.4 146.8
    permeation amount (6 hr)
  • All of the aqueous preparations for external use of Examples 4 to 11 comprising 4 to 6 wt % of isostearic acid showed good skin permeability. There was a tendency that, among them, the preparations having higher contents of the isostearic acid showed superior skin permeability. There was a tendency that the aqueous preparations for external use of Examples 7 to 9 having low contents of the organic amine showed somewhat inferior skin permeability.
  • As shown in FIG. 1, the aqueous preparation for external use according to the present invention had excellent skin permeability and showed up to about 3 times the Diclofenac skin permeability of the commercially available Diclofenac sodium liquid preparation. In particular, the liquid preparation of Example 5 comprising glycerin had a high permeation rate.
    • Examples 12 to 21
  • Aqueous preparations for external use having the compositions (wt %) shown in Table 3 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are shown in Table 3 altogether.
  • The appearance was evaluated according to the following criteria.
  • ∘: Clear solution
    Δ: A transparent solution was obtained, but it separated into an oil phase and an aqueous phase over time or by stimulation of shake or the like
  • A skin permeability test using the franz cell was carried out according to the conventional method for the aqueous preparations for external use of Examples 12 to 15. For the test, skins of swines (Yucatan Micropig, male, 5 months old) were used. Sampling was carried out 8 and 24 hours after the start of the test. The cumulative skin permeation amounts (μg/cm2) are shown altogether in Table 3.
  • TABLE 3
    Ex. 12 Ex. 13 Ex. 14 Ex. 15 Ex. 16 Ex. 17 Ex. 18 Ex. 19 Ex. 20 Ex. 21
    D94 D87 D88 D91 D92 D93 D95 D97 D99 D106
    Diclofenac Na
    10 10 10 10 10 10 10 10 10 10
    Isostearic acid 20 55 20 20 15 10 15 15 20 20
    Lactic acid 5 10 10 10 10 10 5 5 5
    Tartaric acid 5 5 10 5 5 5 3
    Citric acid 5 2
    Triethanolamine 10 40 10 13 10 10 10 5 10 10
    Glycerin 5 5 5 5 5 5 5 10 10 5
    Isopropanol 265 200 265 265 265 265 270 270 265 265
    Pure water 295 305 295 295 295 295 295 295 290 295
    Propylene glycol 295 305 295 292 295 295 295 295 295 295
    Dimethyl isosorbide 90 70 90 90 90 90 90 90 90 90
    total 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000
    pH 5.33 7.48 5.72 6.45 4.9 4.47 5.4 4.8 4.76 5.55
    Appearance ○ ○ ○ ○
    Figure US20210353539A1-20211118-P00003
    Figure US20210353539A1-20211118-P00003
    		 ○
    Figure US20210353539A1-20211118-P00003
    Figure US20210353539A1-20211118-P00003
    		 ○
    Cumulative skin 10 0.31 5.83 1.56
    permeation amount (6 hr)
    Cumulative skin 68.7 56.2 23.6
    permeation amount (24 hr)
  • All of the external preparations within a range of pH 5.0 to 7.5 were stable liquid preparations which did not cause separation or the like even after preservation.
  • A human skin permeability test using the franz cell was carried out according to the conventional method for the prepared aqueous preparation for external use of Example 12 and a commercially available 1% diclofenac sodium gel preparation. A graph indicating transitions of the cumulative skin permeation amounts of the diclofenac is shown in FIG. 2.
    • Examples 2-1 to 2-6
  • Aqueous preparations for external use comprising indomethacin as an active ingredient having the compositions (wt %) shown in Table 4 were produced. The pH of each preparation was measured. Also, the appearance when a glass container was filled with the aqueous preparation for external use was observed with naked eyes. The results are shown in Table 4.
  • The appearance was evaluated according to the following criterion.
  • ∘: Clear solution
  • A skin permeability test using the franz cell was carried out according to the conventional method for the aqueous preparations for external use of Examples 2-1 to 2-5 and the commercially available 1% Indomethacin liquid preparation. For the test, skins of swines (Yucatan Micropig, male, 5 months old) were used. The cumulative skin permeation amounts (μg/cm2) until 24 hours after the start of the test are shown in Table 4.
  • TABLE 4
    Ex. 2-1 Ex. 2-2 Ex. 2-3 Ex. 2-4 Ex. 2-5 Commercial
    194-2 194-3 194-4 194-5 194-6 product
    Indomethacin
    10 10 10 10 10
    Isostearic acid 20 20 20 14 13
    Lactic acid 5 5 5 5 5
    Tartaric acid 5 5 5 5 5
    Triethanolamine 20 25 30 16 13
    Glycerin 5 5 5 5 5
    Isopropanol 265 260 265 265 267
    Pure water 290 290 285 295 295
    Propylene glycol 290 290 285 295 297
    Dimethyl isosorbide 90 90 90 90 90
    total 1000 1000 1000 1000 1000
    pH 6.21 6.72 7.07 5.33 5.25 5.71
    Appearance ○ ○ ○ ○ ○
    Cumulative skin permeation 8.09 4.34 4.25 12.82 17.77 3.37
    amount (μg/cm2)
    • INDUSTRIAL APPLICABILITY
  • The aqueous preparation for external use according to the present invention can be utilized as a liquid preparation which rapidly express an excellent anti-inflammatory analgetic effect, particularly as a liquid preparation which is used by being put into an applicator with a foamed resin or ball attached to its tip.

Claims (6)

1-5. (canceled)
6. An aqueous preparation for external use, comprising an acidic drug or a salt thereof, isostearic acid, an alkanolamine, isopropanol, and propylene glycol, wherein a weight ratio of isopropanol to propylene glycol is in a range of 1:3 to 3:1.
7. The aqueous preparation according to claim 6, further comprising a C2-6 aliphatic hydroxy acid, and having pH 4.5 to 7.8.
8. The aqueous preparation according to claim 7, wherein the C2-6 aliphatic hydroxy acid is one or more selected from the group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
9. The aqueous preparation according to claim 6, wherein the acidic drug is an arylacetic acid nonsteroidal anti-inflammatory analgetic.
10. The aqueous preparation according to claim 6, further comprising glycerin.
US17/382,272 2015-01-30 2021-07-21 Aqueous Preparation for External Use Abandoned US20210353539A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/382,272 US20210353539A1 (en) 2015-01-30 2021-07-21 Aqueous Preparation for External Use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2015016365 2015-01-30
JP2015-016365 2015-01-30
JP2015110902 2015-05-29
JP2015-110902 2015-05-29
PCT/JP2016/052838 WO2016121996A1 (en) 2015-01-30 2016-01-29 Aqueous preparation for external use
US201715546798A 2017-07-27 2017-07-27
US17/382,272 US20210353539A1 (en) 2015-01-30 2021-07-21 Aqueous Preparation for External Use

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2016/052838 Continuation WO2016121996A1 (en) 2015-01-30 2016-01-29 Aqueous preparation for external use
US15/546,798 Continuation US11090265B2 (en) 2015-01-30 2016-01-29 Aqueous preparation for external use

Publications (1)

Publication Number Publication Date
US20210353539A1 true US20210353539A1 (en) 2021-11-18

Family

ID=56543598

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/546,798 Active US11090265B2 (en) 2015-01-30 2016-01-29 Aqueous preparation for external use
US17/382,272 Abandoned US20210353539A1 (en) 2015-01-30 2021-07-21 Aqueous Preparation for External Use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/546,798 Active US11090265B2 (en) 2015-01-30 2016-01-29 Aqueous preparation for external use

Country Status (6)

Country Link
US (2) US11090265B2 (en)
EP (1) EP3251695A4 (en)
JP (2) JP6676548B2 (en)
CN (1) CN107148284A (en)
BR (1) BR112017016010B1 (en)
WO (1) WO2016121996A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6676548B2 (en) * 2015-01-30 2020-04-08 株式会社 メドレックス Aqueous external preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
US20110319399A1 (en) * 2009-03-11 2011-12-29 Kowa Co., Ltd. External preparation containing analgesic/anti-inflammatory agent
US11090265B2 (en) * 2015-01-30 2021-08-17 Medrx Co., Ltd. Aqueous preparation for external use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280426A (en) 1985-06-04 1986-12-11 Ikeda Mohandou:Kk Anti-inflammatory and analgesic application agent
JP3340126B2 (en) * 1990-03-02 2002-11-05 株式会社資生堂 Oil-in-water emulsion composition containing non-steroidal anti-inflammatory drug
JP2523428B2 (en) 1992-12-04 1996-08-07 エスエス製薬株式会社 Anti-inflammatory analgesic gel formulation
EP0788794A4 (en) * 1994-08-09 2000-06-28 Tsumura & Co Composition of external preparation
CN1210463A (en) * 1996-02-07 1999-03-10 株式会社津村 Transparent aqueous solution of diclofenac sodium and medicinal compositions with the use of the same
JP4275751B2 (en) 1996-12-27 2009-06-10 久光製薬株式会社 Composition for external use
KR20050092429A (en) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
JP4820065B2 (en) 2004-05-24 2011-11-24 同仁医薬化工株式会社 Anti-inflammatory analgesic topical aqueous solution
AU2006339350A1 (en) 2005-12-14 2007-09-07 Zars Pharma, Inc. Compositions and methods for dermal delivery of drugs
EP1959930A2 (en) 2005-12-14 2008-08-27 Zars, Inc. Flux-enabling compositions and methods for dermal delivery of drugs
CA2633489C (en) * 2005-12-14 2013-09-24 Zars Pharma, Inc. Compositions and methods for treating dermatological conditions
KR101514342B1 (en) * 2007-11-22 2015-04-22 가부시키가이샤 메드렉스 External preparation composition comprising fatty acid-based inoic liquid as active ingredient
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
JP2014101338A (en) 2012-11-22 2014-06-05 Japan Medic Kk Anti-inflammation and analgesic topical medicament
JP6060742B2 (en) 2013-03-08 2017-01-18 ライオン株式会社 Liquid composition for external use
JP6738120B2 (en) 2013-03-29 2020-08-12 小林製薬株式会社 External pharmaceutical composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
US20110319399A1 (en) * 2009-03-11 2011-12-29 Kowa Co., Ltd. External preparation containing analgesic/anti-inflammatory agent
US11090265B2 (en) * 2015-01-30 2021-08-17 Medrx Co., Ltd. Aqueous preparation for external use

Also Published As

Publication number Publication date
US11090265B2 (en) 2021-08-17
JPWO2016121996A1 (en) 2017-11-09
BR112017016010B1 (en) 2023-02-14
WO2016121996A1 (en) 2016-08-04
US20180015037A1 (en) 2018-01-18
JP2020109111A (en) 2020-07-16
JP6956426B2 (en) 2021-11-02
EP3251695A4 (en) 2018-08-01
EP3251695A1 (en) 2017-12-06
BR112017016010A2 (en) 2018-03-20
CN107148284A (en) 2017-09-08
JP6676548B2 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
JP5704367B2 (en) External preparation composition containing fatty acid ionic liquid as active ingredient
CA2818891C (en) Topical ibuprofen formulations
US9974754B2 (en) Hydrous adhesive patch
WO2011070318A2 (en) Topical formulation
US20210353539A1 (en) Aqueous Preparation for External Use
JP2011088862A (en) Diclofenac sodium-containing aqueous plaster
JP2013223715A5 (en)
KR20190067830A (en) Aqueous patch
KR20190072529A (en) Topical anti-inflammatory composition
JP6503626B2 (en) Pharmaceutical composition
ES2758198T3 (en) Sprayable analgesic compositions
JP5836561B2 (en) Topical skin preparation
JP6322169B2 (en) Topical skin preparation
JP5578778B2 (en) Skin preparation
JP6420102B2 (en) Loxoprofen-containing external solid preparation and storage stabilizer for the external solid preparation
WO2004073680A1 (en) Ointment of droplet-dispersion type
JP2004203835A (en) Ferulic acid-containing composition
JP2014101385A (en) Skin external preparation
WO2019059376A1 (en) Topical agent composition containing compound having 6-deoxy-7,8-dihydro-6-oxomorphine skeleton as medicinal component
JP2018052902A (en) Aqueous solid ointment
JP2014129424A (en) Skin care preparation for external use
JP2014156481A (en) External preparation composition with nucleic acid as active ingredient

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION